A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Phase 2 Completed 43 enrolled Vertex Pharmaceuticals Incorporated

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).

Timeline

Start: 2013-01
Primary completion: 2014-01
Completion: 2014-02

Publications

Genovese MC, Yang F, Ostergaard M, Kinnman N. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis. 2016 Nov;75(11):1979-1983. doi: 10.1136/annrheumdis-2015-208901. Epub 2016 Apr 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	decernotinib	Small molecule	100 mg	Oral
Subject	decernotinib	Small molecule	200 mg	Oral
Subject	decernotinib	Small molecule	300 mg	Oral

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Summary

Timeline

Publications

Drugs

Indications